Mometasonfuroaat Bpm (Mometasone Furoate)

Mometasone furoate binds to glucocorticoid receptors in the cells of the nasal mucosa. This binding alters gene transcription, suppressing the release of inflammatory cytokines, chemokines and other mediators. The result is reduced swelling, mucus production and immune‑cell infiltration, providing localized anti‑inflammatory action.

The dose of Mometasonfuroaat Bpm is determined by the prescribing healthcare professional based on the patient’s age, condition severity and response to therapy. The prescriber will provide specific instructions on the number of sprays per day and duration of treatment.

Safety data for mometasone furoate nasal spray in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning pregnancy or breastfeeding should discuss use with their physician.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Mometasonfuroaat Bpm. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Mometasone furoate is a high‑potency intranasal corticosteroid with a favorable safety profile and minimal systemic absorption. Compared with agents such as fluticasone propionate, it offers similar efficacy in reducing nasal inflammation but may require fewer daily sprays due to its longer residence time in the nasal mucosa.

Store the nasal spray at room temperature, preferably below 25 °C, in its original container. Protect it from excessive moisture, direct sunlight and heat. Keep the device tightly closed when not in use and avoid freezing the product.

The product is administered as a nasal spray. The patient should gently blow the nose, tilt the head slightly forward, insert the tip into one nostril, and spray the prescribed number of actuations while breathing in gently. The process is repeated in the other nostril if directed by the prescriber.

Serious risks, although rare, include severe allergic reactions such as anaphylaxis, development of nasal candidiasis, and ocular complications like glaucoma or cataract formation with prolonged use. Patients should seek immediate medical attention if they experience symptoms such as swelling of the face, difficulty breathing, persistent nosebleeds or visual changes.

Mometasonfuroaat Bpm should not be used by individuals with known hypersensitivity to mometasone furoate or any other component of the formulation. It is also contraindicated in patients who have received live intranasal vaccines within the previous four weeks, as it may diminish vaccine efficacy.